# Vaxcyte (PCVX)

Sector: Vaccine biotechnology

| Field | Value |
|---|---|
| Price | $55.39 |
| Market cap | $8.8B |
| Intrinsic value source | AI estimate |
| Data as of | 2026-11-20 |
| Next earnings | 2027-02-04 (estimate) |

Analysts: Very bullish

Picks: Research only

Discount category: Close to intrinsic value

## In short

The market values Vaxcyte on the chance that VAX-31 wins much of the pneumococcal vaccine market, and strong infant data with a broad FDA approval and a good launch can lift its value.

## Themes and gap

- Themes: Regulation and courts (regulation-legal)
- Gap type: Slow (slow)
- Why: The value depends on FDA approval, which the AI estimate assumes in 2029, and on sales over several years after the launch, although the 2027 data give early evidence.

## About

Vaxcyte, Inc. (PCVX) is based in San Carlos, California. It is a clinical-stage vaccine company. It develops vaccines against bacterial diseases with XpressCF, a cell-free protein synthesis platform that it licenses from Sutro Biopharma. Its main program is VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) for adults and infants. VAX-31 covers more types (serotypes) of pneumococcal bacteria than the vaccines on the market. These bacteria cause pneumonia, meningitis and blood infections. The pipeline also includes VAX-24, a 24-valent PCV, VAX-XL, VAX-A1 against Group A Streptococcus, which is in a Phase 1 study, and VAX-GI against Shigella. Lonza makes key vaccine components for Vaxcyte in a dedicated suite in Visp, Switzerland, and Thermo Fisher will fill the vaccine in Greenville, North Carolina. Vaxcyte has no product sales, and its net loss was $766.6 million in 2025. The common stock trades on Nasdaq in US dollars. Vaxcyte files 10-K and 10-Q reports.

## Thesis

The market values Vaxcyte on the chance that VAX-31 takes a large part of the pneumococcal vaccine market from Pfizer and Merck, and it weighs the risk of the FDA review and the cost of the years before sales start. In October 2026, VAX-31 met all prespecified primary endpoints of OPUS-1, the pivotal Phase 3 trial in adults. But in a separate comparison with Merck's PCV21, two serotypes, 3 and 12F, did not meet the stricter noninferiority limit, and the company expects the FDA to look closely at this comparison. Pfizer, Merck and GSK sold $8.5 billion of pneumococcal vaccines in 2025, and Pfizer plans pivotal trials of a 25-valent vaccine. For the value in the AI estimate to rise, four things must be true. OPUS-2 and OPUS-3 must show good safety and immune responses. The infant Phase 2 study must show strong immune responses with 31 serotypes in one vaccine. Vaxcyte must file the BLA in the first half of 2028 and get approval with a broad recommendation for adults. It must make the vaccine at scale with Lonza and Thermo Fisher. The OPUS-2, OPUS-3 and infant data in the first half of 2027 are the next tests, and the FDA decision, which the AI estimate assumes in 2029, is the main one. If the infant data are weak or the FDA asks for more studies, the value can fall a lot.

## Checkpoints

- Feb 4, 2027 (estimate): Q4 2026 results. Status: Pending. Watch: Cash, cash equivalents and investments stay above $2.9 billion and the company keeps its dates for the OPUS-2, OPUS-3 and infant data and for the BLA, and this passes; a later date fails.
- Jun 2027 (estimate): OPUS-2, OPUS-3 and VAX-31 infant Phase 2 data. Status: Pending. Watch: VAX-31 shows safety similar to licensed vaccines and good immune responses with a flu vaccine, after older pneumococcal vaccines and in infants, and this passes; weak infant responses or a new safety signal fails.

## Valuation

The intrinsic value for Vaxcyte is an AI estimate from November 14, 2026. It is not an analyst's value. An AI research agent calculated it from the filings of Vaxcyte with the SEC. Vaxcyte has no product sales, so the method is a risk-adjusted value of its pneumococcal vaccine franchise, plus net cash, divided by the share count. The value of the franchise is its assumed sales in 2034, the assumed peak year, times an after-tax margin, times 15, discounted for 7 years at 11% (a factor of 0.4817), times a probability of approval of 80%. The margin is after the royalty of 4% of net sales to Sutro Biopharma that the 2025 Form 10-K describes. From this value, the estimate subtracts $3,000 million, the assumed present value of the losses and capital spending before sales cover costs. The Q3 2026 release of November 4, 2026 (Form 8-K) gives cash, cash equivalents and investments of $2,264.4 million at September 30, 2026 and a net loss of $297.1 million for Q3 2026. The Form 8-K of October 9, 2026 gives net proceeds of $544.3 million from the share offering and $558.7 million from $575 million of 1.50% convertible senior notes due 2032. The Q3 2026 10-Q gives finance lease liabilities of $107.8 million and an initial conversion price of about $89.60 per share for the notes. So net cash is $2,684.6 million after the notes and the finance leases. The 10-Q gives 158,299,981 shares at November 2, 2026, pre-funded warrants for 1,517,699 shares at September 30, 2026 and for 400,000 more shares sold in October 2026, 3,113,764 restricted stock units, and 11,698,890 options at an average exercise price of $46.90. The estimate assumes that no pre-funded warrants were exercised in October 2026. It counts the options with the treasury stock method at the October 2026 offering price of $64.00, which adds 3,125,797 shares, so it uses 166,457,241 shares. The 2025 10-K says that Pfizer, Merck and GSK sold $8.5 billion of pneumococcal vaccines in 2025. The sales, the margins, the probability, the discount rate, the multiple, the spending and the weights are assumptions. The low case assumes sales of $2,000 million, because VAX-31 gets only part of the US adult market and the infant program fails, and a margin of 25%. It gives $15.47 per share. The base case assumes sales of $5,000 million, with adults in the US and Europe and a later infant approval, and a margin of 32%. It gives $53.66 per share. The high case assumes sales of $8,000 million, with a leading share in adults and infants, and a margin of 38%. In this case, the value is above the conversion price, so the notes become about 6.42 million shares and are not debt. It gives $103.14 per share. The estimate assumes weights of 25%, 50% and 25%. The weighted intrinsic value is $56.48 per share. Vaxcyte has patents, a licensed cell-free protein platform and a dedicated manufacturing suite at Lonza, which are hard to copy. But it has no approved product and no sales, and Pfizer and Merck have large vaccine businesses and develop broader vaccines too. The estimate does not count on a durable advantage.

As of 2026-11-14.

Sources:

- https://www.sec.gov/Archives/edgar/data/1649094/000164909426000051/pcvx-20261104xexx991.htm
- https://www.sec.gov/Archives/edgar/data/1649094/000164909426000054/pcvx-20260930.htm
- https://www.sec.gov/Archives/edgar/data/1649094/000119312526419174/d150490d8k.htm
- https://www.sec.gov/Archives/edgar/data/1649094/000164909426000007/pcvx-20251231.htm

## Balance sheet

Vaxcyte funds itself with shares and convertible notes. At September 30, 2026, cash and cash equivalents were $125.5 million, short-term investments were $1,166.8 million and long-term investments were $972.2 million, a total of $2,264.4 million. In October 2026, net proceeds of about $1.1 billion from shares, pre-funded warrants and $575 million of 1.50% convertible senior notes due 2032 added to this. Total liabilities were $499.9 million, including accrued contract manufacturing expenses of $159.2 million and finance lease liabilities of $107.8 million for the Lonza suite, and the company had no debt before the notes. Stockholders' equity was $2,489.2 million. The company says that its cash is enough for at least 12 months from November 4, 2026, but that it needs substantial additional capital to complete development and launch its vaccines.

As of 2026-09-30.

Sources:

- https://www.sec.gov/Archives/edgar/data/1649094/000164909426000054/pcvx-20260930.htm
- https://www.sec.gov/Archives/edgar/data/1649094/000164909426000051/pcvx-20261104xexx991.htm
- https://www.sec.gov/Archives/edgar/data/1649094/000119312526419174/d150490d8k.htm

## Dividends

Vaxcyte does not pay a dividend.

Source: company filings and market data, read on 2026-11-13.

## Recent events

- 2026-11-04: Vaxcyte reported a Q3 2026 net loss of $297.1 million and cash, cash equivalents and investments of $2,264.4 million at September 30, 2026, or about $3.4 billion with the October offerings. The Phase 1 study of VAX-A1 moved to Stage 2 after a safety board review, with the Low and Mid Dose groups first. The 10-Q says that the dedicated Lonza suite was certified for commercial operation in August 2026.
- 2026-10-09: Vaxcyte closed offerings of 8,584,375 shares at $64.00, pre-funded warrants for 400,000 shares and $575 million of 1.50% convertible senior notes due 2032, with a conversion price of about $89.60. Net proceeds were about $1.1 billion.
- 2026-10-05: VAX-31 met all prespecified primary endpoints in OPUS-1, the pivotal Phase 3 trial in 4,047 US adults, against PCV20 and PCV21, with a safety profile similar to both. Against PCV21 alone, serotypes 3 and 12F met only the older, less strict noninferiority limit.
- 2026-09-03: Vaxcyte appointed Luis Jodar, a former Chief Medical Officer for vaccines at Pfizer, as Chief Medical Officer, and David McAvoy, a former Chief Legal Officer of Teva, as Chief Legal Officer.
- 2026-08-05: Vaxcyte reported cash, cash equivalents and investments of $2.5 billion at June 30, 2026. In June 2026, it started the first study of VAX-A1 in people.
- 2026-05-06: Vaxcyte said that enrollment was complete in all three adult Phase 3 trials of VAX-31 (OPUS-1, OPUS-2 and OPUS-3).
- 2026-02-24: Vaxcyte reported a 2025 net loss of $766.6 million. Lonza completed the dedicated manufacturing facility for Vaxcyte's vaccines, and Vaxcyte signed a sales agreement to sell up to $500 million of shares over time.
- 2026-02-02: Vaxcyte closed an offering of 12,650,000 shares at $50.00 per share, for gross proceeds of $632.5 million.

## Latest news and filings

- Last earnings: 2026-11-04 (8-K: https://www.sec.gov/Archives/edgar/data/1649094/000164909426000051/)
- Next earnings: 2027-02-04 (expected; the company has not confirmed it)

| Filed | Form | Headline | Period end | XBRL document | Link |
| --- | --- | --- | --- | --- | --- |
| 2026-11-04 | 10-Q | Quarterly report for the period ended Sep 30, 2026 | 2026-09-30 | pcvx-20260930 | https://www.sec.gov/Archives/edgar/data/1649094/000164909426000054/pcvx-20260930.htm |
| 2026-11-04 | 8-K | Earnings release |  | pcvx-20261104 | https://www.sec.gov/Archives/edgar/data/1649094/000164909426000051/ |
| 2026-10-09 | 8-K | New material agreement and New debt or financial obligation |  |  | https://www.sec.gov/Archives/edgar/data/1649094/000119312526419174/d150490d8k.htm |
| 2026-10-05 | 8-K | Investor disclosure and Other company news |  |  | https://www.sec.gov/Archives/edgar/data/1649094/000119312526413168/d21202d8k.htm |
| 2026-09-03 | 8-K | Change of directors or officers and Investor disclosure |  | pcvx-20260831 | https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/pcvx-20260831.htm |
| 2026-08-05 | 10-Q | Quarterly report for the period ended Jun 30, 2026 | 2026-06-30 | pcvx-20260630 | https://www.sec.gov/Archives/edgar/data/1649094/000164909426000043/pcvx-20260630.htm |
| 2026-08-05 | 8-K | Earnings release |  | pcvx-20260805 | https://www.sec.gov/Archives/edgar/data/1649094/000164909426000041/ |
| 2026-07-15 | 8-K | Change of directors or officers |  | pcvx-20260713 | https://www.sec.gov/Archives/edgar/data/1649094/000164909426000030/pcvx-20260713.htm |
| 2026-06-23 | 8-K | Change of directors or officers |  | pcvx-20260617 | https://www.sec.gov/Archives/edgar/data/1649094/000164909426000026/pcvx-20260617.htm |
| 2026-06-16 | 8-K | Shareholder vote results |  | pcvx-20260615 | https://www.sec.gov/Archives/edgar/data/1649094/000164909426000021/pcvx-20260615.htm |

Every filing on SEC EDGAR (CIK 1649094): https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001649094&type=&dateb=&owner=include&count=40

## Risks

- High: In OPUS-1, serotypes 3 and 12F did not meet the stricter noninferiority limit against PCV21. The FDA can ask for more data, delay the approval or give a narrower label.
- High: The infant market is larger than the adult market, and a vaccine with many serotypes can give weaker immune responses. In the VAX-24 infant study, the Low and Mid doses met the seroconversion criteria for 20 of 24 serotypes. The VAX-31 infant data come by mid-2027.
- High: Pfizer had 77% of pneumococcal vaccine sales in 2025, and it plans pivotal trials of a 25-valent vaccine. Merck sells PCV21 for adults. A broader competing vaccine can reduce the share of VAX-31.
- Medium: Vaxcyte lost $902.0 million in the first nine months of 2026 and says that it needs substantial additional capital to make and sell its vaccines. More share sales can dilute shareholders, and the 2032 notes can become about 6.4 million shares.
- Medium: Use and payment of vaccines in the US depend on recommendations of the CDC's Advisory Committee on Immunization Practices (ACIP), and a weak recommendation can limit sales.
- Medium: Vaxcyte depends on Lonza for key vaccine components and on Thermo Fisher to fill the vaccine. A problem at one plant can delay the launch or limit supply.

## Links

- Page: https://picks.utilarium.app/company/PCVX/
- History of changes: https://picks.utilarium.app/company/PCVX/history/
- JSON with full history: https://picks.utilarium.app/data/company/PCVX.json

> Picks is a personal record of stock picks. It gives general opinions about stocks, including a "Top pick" label. They are not tailored to your needs, goals or risk tolerance. Kevin is not a registered adviser and relies on the general-advice exemption in Canadian securities law (NI 31-103 s.8.25). Do your own research, or ask a registered adviser. Kevin may hold any stock on this site. Prices, intrinsic values and ratings can be delayed or wrong; check the original source. Full disclaimer: /disclaimer/.
